Radiotherapy Side Effect Clinical Trial
Official title:
Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | February 28, 2029 |
Est. primary completion date | February 28, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis. - Sign informed consent. - Between the ages of 18 and 70. - ECOG general status score of 0-2. - The expected survival is at least 6 months. - Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) =1.5 x 109/L, platelet count =80 x 109/L, hemoglobin =9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine =1.5 times the upper limit of normal or calculated creatinine clearance =50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less. Exclusion Criteria: - Complicated with other malignant tumors that have not been controlled. - Have large quantity of pleural or pericardial effusion. - Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs. - Chest radiation therapy or radioactive particle implantation history. - Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area. - Pregnancy (confirmed by serum or urine ß-HCG test) or lactation period. - HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis. - A history of mental illness may hinder the completion of treatment. - With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy. - Other circumstances that the physician considers inappropriate to participate in clinical study. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Proton and Heavy Ion Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Jian Chen |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease progression-free survival rate | Disease progression-free survival rate was defined from the start of carbon ion radiotherapy till the date of disease progression at any site or death, or the last follow up. | From date of radiotherapy started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | |
Primary | Incidence of Treatment-induced Adverse Events | Treatment-induced toxicities were scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, for events observed after the first dose of irradiation. Toxicities occurred 90 or more days after the completion of CIRT were defined as late toxicities. | From date of radiotherapy started, every 3-4 months within the first 2 years, every 6 months between years 3 and 5, and annually thereafter, assessed up to 100 months. | |
Secondary | Local-progression free survival rate | Local-progression free survival rate was defined from the start of carbon ion radiotherapy till the date of local progression or the last follow-up. | From date of radiotherapy started until the date of first documented local disease progression, assessed up to 100 months. | |
Secondary | Overall survival rate | Overall survival rate was defined from the start of carbon ion radiotherapy till the date of death or the last follow-up. | From date of radiotherapy started until the date of death from any cause, assessed up to 100 months. | |
Secondary | Cause-specific survival rate | Cause-specific survival rate was defined from the start of carbon ion radiotherapy till the date of death caused by thymus tumor treated in this study or the last follow-up. | From date of radiotherapy started until the date of death caused by thymus tumor treated in this study , assessed up to 100 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05543239 -
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain
|
N/A | |
Terminated |
NCT04535908 -
Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.
|
N/A | |
Recruiting |
NCT04115267 -
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
|
||
Recruiting |
NCT05820633 -
Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.
|
N/A | |
Completed |
NCT05880446 -
PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)
|
N/A | |
Recruiting |
NCT05724004 -
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
|
N/A | |
Recruiting |
NCT04612907 -
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
|
N/A | |
Recruiting |
NCT05762900 -
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT03613506 -
The Role and Intervention of TGF-β in Abdominal Radiation Injury
|
Phase 2 | |
Completed |
NCT06353724 -
Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent
|
N/A | |
Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
Recruiting |
NCT05224297 -
Patient Experience Data in Radiation Oncology
|
||
Recruiting |
NCT05776147 -
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
|
||
Completed |
NCT04842409 -
Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
|
||
Recruiting |
NCT03742687 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
N/A | |
Not yet recruiting |
NCT05614700 -
Prostate Reirradiation Toxicity Outcomes Feasibility Study
|
N/A | |
Completed |
NCT04027543 -
Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)
|
||
Recruiting |
NCT05354596 -
A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).
|
N/A | |
Recruiting |
NCT03378856 -
Evaluation of Technological Innovation in Radiotherapy
|